Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
about
Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysisMicroscopic-observation drug-susceptibility assay for the diagnosis of TBGlobal plagues and the Global Fund: Challenges in the fight against HIV, TB and malariaScreening for Tuberculosis Among Adults Newly Diagnosed With HIV in Sub-Saharan Africa: A Cost-Effectiveness AnalysisEuropean union standards for tuberculosis careIsoniazid Mono-Resistant Tuberculosis: Impact on Treatment Outcome and Survival of Pulmonary Tuberculosis Patients in Southern Mexico 1995-2010Cost-effectiveness of treating multidrug-resistant tuberculosisFeasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the PhilippinesTuberculosis recurrence and mortality after successful treatment: impact of drug resistanceOutcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosisAre survey-based estimates of the burden of drug resistant TB too low? Insight from a simulation studyScaling up programmatic management of drug-resistant tuberculosis: a prioritized research agendaThe infectiousness of tuberculosis patients coinfected with HIVFollow-up of patients with multidrug resistant tuberculosis four years after standardized first-line drug treatmentTransmission of MDR and XDR tuberculosis in Shanghai, ChinaStandardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysisTreatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infectionEffectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort studyHow do patients who fail first-line TB treatment but who are not placed on an MDR-TB regimen fare in South India?Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysisUse of a molecular diagnostic test in AFB smear positive tuberculosis suspects greatly reduces time to detection of multidrug resistant tuberculosisMultidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patientsThe cost-effectiveness of tuberculosis preventive therapy for HIV-infected individuals in southern India: a trial-based analysisTargeting the chromosome partitioning protein ParA in tuberculosis drug discoveryAggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityThe impact of isoniazid resistance on the treatment outcomes of smear positive re-treatment tuberculosis patients in the state of Andhra Pradesh, IndiaThe importance of implementation strategy in scaling up Xpert MTB/RIF for diagnosis of tuberculosis in the Indian health-care system: a transmission modelHas introduction of rapid drug susceptibility testing at diagnosis impacted treatment outcomes among previously treated tuberculosis patients in Gujarat, India?Progressive Hemorrhage and Myotoxicity Induced by Echis carinatus Venom in Murine Model: Neutralization by Inhibitor Cocktail of N,N,N',N'-Tetrakis (2-Pyridylmethyl) Ethane-1,2-Diamine and SilymarinGenoType MTBDRplus Assay for Rapid Detection of Multidrug Resistance in Mycobacterium tuberculosis: A Meta-AnalysisThe Role of Adherence and Retreatment in De Novo Emergence of MDR-TBPrevalence, Risk Factors, and Treatment Outcomes of Isoniazid- and Rifampicin-Mono-Resistant Pulmonary Tuberculosis in Lima, PeruEffects of Multidrug Resistant Tuberculosis Treatment on Patients' Health Related Quality of Life: Results from a Follow Up StudyA Multistrain Mathematical Model To Investigate the Role of Pyrazinamide in the Emergence of Extensively Drug-Resistant TuberculosisCost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.On the spread and control of MDR-TB epidemics: an examination of trends in anti-tuberculosis drug resistance surveillance data.Tuberculosis treatment outcome in the European Union and European Economic Area: an analysis of surveillance data from 2002-2011.Microscopic observation drug susceptibility assay, a rapid, reliable diagnostic test for multidrug-resistant tuberculosis suitable for use in resource-poor settings.Impact of DOTS expansion on tuberculosis related outcomes and costs in HaitiTreatment of isoniazid-resistant pulmonary tuberculosis.
P2860
Q24554274-D92ABC33-40C4-4B3B-B89F-090DC0FF35DEQ24683727-4F42F1DB-AC50-4BBC-AE9F-2E479D2B89D3Q24796880-49824CE6-06E4-4A46-845A-95DC191572A4Q26779464-89CCBFC9-E76C-4AA7-B545-E4B7E848BB69Q26823223-998B4596-BAAE-4BEB-8BE3-6C6610ADEEB5Q28468519-EA71EBF1-AC11-4689-AD6E-584A086B5B8AQ28469015-1A971F58-3B89-4608-90B4-769704AB0449Q28469046-6B3CFB8B-CD2E-45CE-8328-43FED70C2ADDQ28469052-CFF96D0D-3D7A-4888-9C20-0544D740D0A3Q28471986-60D2BECA-68A1-4E3A-981F-463FA2BF84C8Q28472943-B9E3ADF8-1F43-4D66-A3B6-216831A014AAQ28473126-D76E22BC-63FE-419A-807F-A7C604ABC663Q28473650-200F71B6-8AA7-4767-AF12-5AF96C091B51Q28474035-3E5899C6-ECE6-48C1-9FD4-AE4B4027CC3FQ28474677-E9B5EA85-8BDC-4041-873C-A4D1764A3DDFQ28476125-1D519EEC-A8FB-4BD2-8BFB-437062280D52Q28476640-E05C6017-6995-417D-8E73-03DB1D29A935Q28477435-F1D74880-287B-4715-9954-ACFCB9C2D935Q28477451-DDFFFF80-EF0A-47C7-9C10-E05270609F8BQ28477855-B1F0F51D-BC11-45F0-8B1C-1D34B51EA214Q28480576-19D9B285-C090-42C5-98BB-91EBA39A8E80Q28482730-5BE5C96E-BFA5-4584-BE2F-784FA0B4109CQ28483035-853F6235-7835-4B5F-A515-434C206BB3D2Q28486773-1DF33488-B138-4161-92F1-C901DEBC76EEQ28487938-DD24A458-419B-45CA-83FF-01D0B325BBD3Q28534364-98CA80DC-6AF8-488C-BEB5-31499B76F7C2Q28540733-5BB7C51F-E131-40A6-9C1E-CFB88EACDC3DQ28546196-DF6E819A-0504-48E7-8A8E-F12BF1A0C0CCQ28547272-AB8B18B7-4CB9-4CDE-92BE-07373C50520EQ28550477-51BF1F06-2EC4-46AE-A56D-3E81956B5968Q28550707-6A86E343-A329-4AA5-9C17-DBE7A3653632Q28551162-6B439737-5813-41BC-BCBB-A9817815BC4EQ28553181-E9BBE222-38CE-4E85-B063-45D3DCA3B93FQ29048653-B0B776F1-8243-4FD1-96EC-9227A0F666B0Q30830344-D0AC4819-2270-464B-AE8A-9D1A4FD5CE2DQ30873423-B6084E98-D230-44FD-8B25-244E2426BBC8Q31032509-E7ED97A6-70C6-4CAF-8BA4-76D30077C528Q31119394-82B1C040-C154-4E82-BC67-49810E008D6FQ33254073-E95B4743-BB5A-4A13-A7CC-E24F994EE96FQ33315736-B96FFD54-4081-4BB4-8A3A-6D06BE74F547
P2860
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Standard short-course chemothe ...... tment outcomes in 6 countries.
@en
Standard short-course chemothe ...... tment outcomes in 6 countries.
@nl
type
label
Standard short-course chemothe ...... tment outcomes in 6 countries.
@en
Standard short-course chemothe ...... tment outcomes in 6 countries.
@nl
prefLabel
Standard short-course chemothe ...... tment outcomes in 6 countries.
@en
Standard short-course chemothe ...... tment outcomes in 6 countries.
@nl
P2093
P356
P1476
Standard short-course chemothe ...... tment outcomes in 6 countries.
@en
P2093
A G Khomenko
M A Espinal
M C Raviglione
P G Suarez
P304
P356
10.1001/JAMA.283.19.2537
P407
P577
2000-05-01T00:00:00Z